Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark X Sliwkowski

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Science (New York, N.Y.)|September 14, 2013
Antibody therapeutics in cancerMark X Sliwkowski, Ira Mellman
Oncology|November 8, 2002
Perspectives on anti-HER monoclonal antibodiesMalcolm Ranson, Mark X Sliwkowski
Seminars in Oncology|July 4, 2003
Preclinical studies with Erlotinib (Tarceva)Robert W Akita, Mark X Sliwkowski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Toward an effective targeted chemotherapy for multiple myelomaAndrew G Polson, Mark X Sliwkowski
The Journal of Biological Chemistry|August 28, 2002
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitorJennifer Stamos, Mark X Sliwkowski, Charles Eigenbrot
Biochimica Et Biophysica Acta|July 29, 2014
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancerThuy Vu, Mark X Sliwkowski, Francois X Claret
The Journal of Biological Chemistry|May 10, 2002
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent associationElicia Penuel, Robert W Akita, Mark X Sliwkowski
Cancer Research|April 3, 2004
Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effectsJames G Jackson, Patricia St Clair, Mark X Sliwkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2011
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancerPatricia M LoRusso, Denise Weiss, Ellie Guardino, et al.
Breast Cancer Research and Treatment|August 24, 2010
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerTeemu T Junttila, Guangmin Li, Kathryn Parsons, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Science (New York, N.Y.)|September 14, 2013
Antibody therapeutics in cancerMark X Sliwkowski, Ira Mellman
Oncology|November 8, 2002
Perspectives on anti-HER monoclonal antibodiesMalcolm Ranson, Mark X Sliwkowski
Seminars in Oncology|July 4, 2003
Preclinical studies with Erlotinib (Tarceva)Robert W Akita, Mark X Sliwkowski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Toward an effective targeted chemotherapy for multiple myelomaAndrew G Polson, Mark X Sliwkowski
The Journal of Biological Chemistry|August 28, 2002
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitorJennifer Stamos, Mark X Sliwkowski, Charles Eigenbrot
Biochimica Et Biophysica Acta|July 29, 2014
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancerThuy Vu, Mark X Sliwkowski, Francois X Claret
The Journal of Biological Chemistry|May 10, 2002
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent associationElicia Penuel, Robert W Akita, Mark X Sliwkowski
Cancer Research|April 3, 2004
Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effectsJames G Jackson, Patricia St Clair, Mark X Sliwkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2011
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancerPatricia M LoRusso, Denise Weiss, Ellie Guardino, et al.
Breast Cancer Research and Treatment|August 24, 2010
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerTeemu T Junttila, Guangmin Li, Kathryn Parsons, et al.
Pageof 5